Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
Neurodegenerative diseases are the top 3 leading causes of death and are viewed now as systemic diseases. Adaptive immunity including a T-cell response in the central nervous system (CNS) likely contributes to disease pathogenesis...
Neurodegenerative diseases are the top 3 leading causes of death and are viewed now as systemic diseases. Adaptive immunity including a T-cell response in the central nervous system (CNS) likely contributes to disease pathogenesis. How T cells are primed and recruited to CNS is largely unexplored, due to the complexity of the process and lack of tools and animal models. I will study these questions on the most common genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here, a GGGGCC repeat expansion in the C9orf72 gene causes haploinsufficiency through reduced C9orf72 protein expression, and gain-of-function toxicities through repeat RNA and its translation to aggregating dipeptide repeats (DPRs). A synergistic role of these pathomechanisms is suspected but not clearly identified.
I propose that T cells are the missing piece of the puzzle for the synergistic effects of C9orf72 haploinsufficiency and DRP toxicity and will explore a) whether peripheral antigen-presenting cells (APCs) and CNS microglia present DPRs to prime antigen-specific T-cell response; b) whether C9orf72 haploinsufficiency alters antigen presentation of microglia and APCs; c) whether T cells mediate synergic effects of C9orf72 haploinsufficiency and DRP toxicity.
This novel project for the first time addresses peripheral and CNS activation of T cells against DPRs in C9orf72 ALS/FTD and reveals novel mechanism on synergistic effect of C9orf72 haploinsufficiency and DPR toxicity. It offers a unique integration of neurobiological tools, immunological methods, and single-cell-level approaches. It brings solid evidence on the antigen presentation of endogenous aggregating protein to drive antigen-specific T-cell response, which will broad the understanding on ALS/FTD and other neurodegenerative diseases. It presents a promising research trajectory for the identification of new biomarkers, breakthrough therapeutic targets and the development of novel interventions.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.